In recent years, in patients with chronic kidney disease (CKD) without transplantation, promising results have been achieved with the addition of sodium-glucose co-transporter 2 inhibitors (SGLT2-Is), glucagon-like peptide-1 (GLP-1) agonists, and new-generation nonsteroidal mineralocorticoid receptor antagonists (MRAs) such as finerenone, or combinations of these drugs, in addition with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) [3,4,5,6]. This evidence concerns the gene SLC5A2 and chronic kidney disease.